Neil Schaffner, MD
Endocrinology, Diabetes & Metabolism · Opelika, ALNPI 1184684953
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $575,422 of the $641,804 with a category attached, or 89.7%. Lilly USA, LLC accounts for 67.8% of it on its own, with 50 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,581 payments — averaging $405.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$435K
- AstraZeneca$129K
- Sanofi-aventis U.S. LLC$65K
- Abbott$5K
- Novo Nordisk$1K
- Medtronic$1K
- plus $5K from 45 others
Across 3 payments — averaging $37.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk$38
- GSK$38
- AstraZeneca$38
What the payments were for
- Consulting fees$5,0001%
- Speaking & faculty fees$575,42290%
- Travel & lodging$38,6686%
- Food & beverage$22,6804%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$311,658
- FARXIGA$125,475
- TRULICITY$102,087
- SOLIQUA 100/33$45,016
- TOUJEO$31,067
- FREESTYLE LIBRE 3$4,300
- ZEPBOUND$3,825
- MINIMED 780G$692
- FreeStyle Libre 2$145
- SIMPLERA SENSOR$130
How this compares
$641,804 in reported general payments places this provider in the 95th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 372 | $413,521 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 178 | $193,127 |
| Xigduo XrDapaglifloz Propaned/Metformin | 185 | $130,029 |
| FarxigaDapagliflozin Propanediol | 112 | $103,920 |
| TrulicityDulaglutide | 78 | $92,230 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 63 | $68,155 |
| JardianceEmpagliflozin | 69 | $63,086 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $42,543 |
| SynthroidLevothyroxine Sodium | 394 | $38,546 |
| OzempicSemaglutide | 23 | $37,227 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $33,958 |
| LyumjevInsulin Lispro-Aabc | 20 | $23,194 |
| Humalog Kwikpen U-100Insulin Lispro | 70 | $19,389 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $14,742 |
| FiaspInsulin Aspart (Niacinamide) | 13 | $12,315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro | $435,461 | $541,058540 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $164 | $131,241132 claims |
| AstraZenecaFarxiga | $128,647 | $103,920112 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $1,198 | $54,68650 claims |
| AbbVieSynthroid | $310 | $38,546394 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $118 | $5,972380 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Opelika
- Bantwal BaligaOpelika$483K
- Ralph TeagueBirmingham$487K
- William GarveyBirmingham$421K
- Judson MenefeeFairhope$168K
- William DebellTuscaloosa$161K
- Edison GoncalvesBirmingham$142K
- David BellIrondale$112K
- Bethany JacksonFlorence$90K
- Dwain WoodeHuntsville$78K
- Fernando BrilBirmingham$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.